

Truth in Testimony Disclosure Form

In accordance with Rule XI, clause 2(g)(5)*, of the *Rules of the House of Representatives*, witnesses are asked to disclose the following information. Please complete this form electronically by filling in the provided blanks.

Committee: Energy and Commerce

Subcommittee: Oversight and Investigations

Hearing Date: April 10, 2019

Hearing Title :

PRICED OUT OF A LIFESAVING DRUG: GETTING ANSWERS ON THE RISING COST OF INSULIN

Witness Name: Kathleen Tregoning

Position/Title: Executive Vice President, External Affairs

Witness Type: ☐ Governmental ☒ Non-governmental

Are you representing yourself or an organization? ☐ Self ☒ Organization

If you are representing an organization, please list what entity or entities you are representing:

Sanofi US

If you are a **non-governmental witness**, please list any federal grants or contracts (including subgrants or subcontracts) related to the hearing's subject matter that you or the organization(s) you represent at this hearing received in the current calendar year and previous two calendar years. Include the source and amount of each grant or contract. *If necessary, attach additional sheet(s) to provide more information.*


Please see attached.

If you are a **non-governmental witness**, please list any contracts or payments originating with a foreign government and related to the hearing's subject matter that you or the organization(s) you represent at this hearing received in the current year and previous two calendar years. Include the amount and country of origin of each contract or payment. *If necessary, attach additional sheet(s) to provide more information.*

Currently and in the previous two calendar years, Sanofi US has no contracts or payments with any foreign governments relating to the pricing of insulin in the United States.

False Statements Certification

Knowingly providing material false information to this committee/subcommittee, or knowingly concealing material information from this committee/subcommittee, is a crime (18 U.S.C. § 1001). This form will be made part of the hearing record.



Witness signature

April 8, 2019
Date

If you are a non-governmental witness, please ensure that you attach the following documents to this disclosure. Check both boxes to acknowledge that you have done so.

☒ Written statement of proposed testimony

☒ Curriculum vitae or biography

*Rule XI, clause 2(g)(5), of the U.S. House of Representatives provides:

(5)(A) Each committee shall, to the greatest extent practicable, require witnesses who appear before it to submit in advance written statements of proposed testimony and to limit their initial presentations to the committee to brief summaries thereof.

(B) In the case of a witness appearing in a nongovernmental capacity, a written statement of proposed testimony shall include a curriculum vitae and a disclosure of any Federal grants or contracts, or contracts or payments originating with a foreign government, received during the current calendar year or either of the two previous calendar years by the witness or by an entity represented by the witness and related to the subject matter of the hearing.

(C) The disclosure referred to in subdivision (B) shall include—

(i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and

(ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government.

(D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form not later than one day after the witness appears.

If you are a non-governmental witness, please list any federal grants or contracts (including subgrants or subcontracts) related to the hearing's subject matter that you or the organization(s) you represent at this hearing received in the current calendar year and previous two calendar years. Include the source and amount of each grant or contract. If necessary, attach additional sheet(s) to provide more information.

Sanofi US contracts with a number of U.S. federal agencies in order to allow such agencies to purchase Sanofi products. The current federal contracts that cover Sanofi insulin products (including the Lantus product line, Toujeo product line, Admelog product line, and Soliqua 100/33) are listed below:

Contract #	Type of Contract	Federal party	Eff. Date	Description
V797D-70230	Sanofi US Federal Supply Schedule (FSS)	All U.S. federal Gov't Agencies	9/15/2017	Contract through which federal Government agencies may purchase Sanofi products, including all insulin products
UFBPA HT9402-17-A-0013	Lantus Blanket Purchase Agreement (BPA)	U.S. Department of Defense (DOD)	11/1/2017	Contract through which the DOD may purchase Lantus SoloStar at an additional discount (Note: original Lantus BPA effective date is 6/1/2010)
UFBPA HT9402-17-A-0014	Lantus BPA	DOD	11/1/2017	Contract through which the DOD may purchase Lantus SoloStar at an additional discount (Note: original Lantus BPA effective date is 6/1/2010)
UFBPA HT9402-17-A-0015	Toujeo BPA	DOD	11/1/2017	Contract through which the DOD may purchase Toujeo at an additional discount
UFBPA HT9402-18-A-0015	Admelog BPA	DOD	9/10/2018	Contract through which the DOD may purchase Admelog at an additional discount
Tricare Retail Refund Pricing Agreement	Tricare Retail Pharmacy Refund	DOD/Tricare	6/1/2009	Standard discount contract for Tricare utilization, including all insulin products
RFQ HT9402-17-Q-0006	Additional Discount Program (ADP)	DOD/Tricare	11/22/2017	Additional discount for Lantus and Toujeo Tricare utilization (Note: original Lantus ADP effective date is 1/1/2011)
RFQ HT9402-18-Q-0003	Additional Discount Program	DOD/Tricare	8/22/2018	Additional discount for Admelog Tricare utilization
V797D-70230_TPR_P00039	Lantus Temporary Price Reduction (TPR)	U.S. Department of Veterans Affairs (VA)	1/1/2019	TPR for Lantus offered to VA entities (Note: this effective date is a renewal of previous TPR. Original Lantus TPR effective date is 1/1/2012)

V797D-70230_TPR_P00040	Lantus TPR	Indian Health Service (IHS)	10/18/2018	Temporary Price Reduction for Lantus offered to IHS entities
------------------------	------------	-----------------------------	------------	--

Additionally, from time to time, principal clinical trial investigators affiliated with Sanofi may receive NIH grant funding or collaborate with NIH to develop new vaccines. We have not identified any such grants or collaborations related to insulin products currently or in the previous two calendar years.